Investment Sought:
£2m for 28.6% equity
(Q3 2021)

Our mission is to be the gel supplier of choice for global drug development and regenerative medicine.

Click here to register your interest

How UNI-GEL works?

UNI-GEL is a platform solution for drug discovery and regenerative medicine through the ability to

  • mimic the human body to support cell culture for drug discovery.
  • flex to the required tunability to mimic different parts of the body
  • be used within printable biocompatible bio-inks for regenerative medicine.

Target markets

  • Short-comings in predictive modelling are impeding effective drug discovery and regenerative medicine techniques
  • Regenerative medicine requires biomaterials, scaffolds and cells generated from robust and reliable materials
  • 3D-Bioprinting offers potential to implant tissue therapeutics rather than whole organs in a consistent and safe manner
  • Cell Based Assay Mkt $22bn in 2025
  • Regenerative Market $39m in 2023

B2B Proposition:

1.HYDROGELS that are a superior alternative to Matrigel

2.BIO-INKS which will be utilized in large scale regenerative medicine.

Peptide hydrogels combine all the key attributes that are essential for robust and highly reproducible cell-derived data.

Ease of use and regenerative adaptability make biogelx a future market leader.

Our approach

Our mission is to be the gel supplier of choice for global drug development and regenerative medicine

Company BioGelx Ltd

BioCity Scotland, Newhouse, Scotland

Traction
  • Achieving ISO9001 Certification
  • Recruitment of 7 new PhD projects utilising either the hydrogels or bioinks due to start in October 2021.
  • Establishing a Scientific Advisory Board in Nov 20 – Professors Matthew Dalby and Manuel Salmeron-Sanchez (Glasgow University) and Paul Smith (CEO Bioascent).
  • Securing space to establish cell culture capabilities (April 2021)
  • Attracting an experienced cell culture expert through UKRI Innovation Scholar secondment; starts July 2021.
Valuation

£5m pre-money

Investment sought

£2.0m for 28.6% equity (Q3 2021)

Use of funds
  • Develop Product Portfolio to include growth factors to enhance biological performance.
  • Implement cell culture capabilities within laboratories at Biocity Glasgow
  • Scientific team expansion 5 scientists/cell biologists and 2 business development
  • Sales and marketing team expansion
  • Capital expenditure to support technology development.
  • Fund Collaborations to generate case studies and market evidence
Existing investors Strathclyde University

Scottish Investment Bank

Founders

EIS Investors

Leadership Dr Alison Clayton. CEO. 25yrs+ in operational and scientific leadership.

Dr Mhairi Rodgers. Heads of Ops. Specialist in biotechnology and 3D biomaterials.

Dr Chris Allan. Senior Scientist, responsible for new product development.

John Waddell Chairman. Extensive experience of driving value to successful exit.

Margaret Temple Non-Exec. Experienced BD and exiting in the Life Sciences Industry.

Prof Rein Ulijn, Founder and  Director, Champion of biomolecular nanoscience

Disclaimer

The content of this communication has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Reliance on this communication for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested.

Find out more

To find out more or register your interest in this investment opportunity simply fill in and submit the form below and we will be in touch with you shortly.